Table 3 Multivariate analysis of clinicopathological variables in relation to recurrence-free survival and overall survival in discovery cohort.
Variable | Recurrence-free survival | Overall survival | ||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
KRAS mutation in ctDNA | ||||
No | 1.0 (reference) | 0.559 | 1.0 (reference) | 0.609 |
Yes | 1.2 (0.6–2.3) | 1.2 (0.6–2.3) | ||
KRAS G12D mutation in ctDNA | ||||
No | 1.0 (reference) | <0.001 | 1.0 (reference) | 0.001 |
Yes | 5.1 (2.2–11.8) | 4.0 (1.8–9.4) | ||
Radiologic tumour size, cm | ALL | 0.002 | ALL | 0.004 |
≤2 | 1.0 (reference) | 1.0 (reference) | ||
>2, ≤4 | 2.3 (1.1–4.9) | 0.024 | 2.1 (1.0–4.5) | 0.052 |
>4 | 8.4 (2.6–26.9) | <0.001 | 7.2 (2.2–22.9) | 0.001 |
Pathological stage (AJCC, 8th edition) | ALL | <0.001 | ALL | <0.001 |
IA | 1.0 (reference) | 1.0 (reference) | ||
IB | 0.8 (0.3–2.0) | 0.581 | 1.0 (0.3–3.0) | 0.989 |
IIA | 0.3 (0.1–1.2) | 0.097 | 0.5 (0.1–2.1) | 0.327 |
IIB | 1.9 (0.8–4.6) | 0.16 | 2.8 (1.1–7.6) | 0.04 |
III | 18.4 (6.1–55.7) | <0.001 | 34.8 (10.1–120.2) | <0.001 |
